PDCD1 and neoplasm: These results indicate that miltefosine improves the efficacy of hypofunctional CAR-T cells in a PD-1/PD-L1-independent manner (Figure S3C) and suggest that miltefosine may have therapeutic benefits in the tumor microenvironment in which the PD-1/PD-L1 blockade is nonfunctional.